AstraZeneca

FOB Synthesis, AstraZeneca collaborate on antibiotic-resistant bacterial infections

Wednesday, January 29, 2014 01:02 PM

FOB Synthesis, a chemistry-driven drug discovery and custom synthesis company, has entered into an R&D option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca's preclinical beta lactamase inhibitor (BLI) and FOB Synthesis' preclinical Carbapenem antibiotic programs to help break down bacteria's resistance to carbapenems.

More... »

WIRB Copernicus Group

PTC Therapeutics expands management team

Monday, January 27, 2014 02:47 PM

PTC Therapeutics has expanded its senior management team with the appointment of Robert J. Spiegel, M.D., FACP, to chief medical officer and Murad Husain to vice president, Global Regulatory Affairs. PTC also announced the promotions of Joseph Colacino, Ph.D., to senior vice president, Drug Discovery and Ernest R. Dietel to senior vice president, Quality. In addition, Jay Barth, M.D., senior vice president of Clinical Development, is leaving PTC to pursue other opportunities.

More... »


Former U.K. AstraZeneca R&D site to become science, technology park

Monday, January 20, 2014 11:56 AM

Loughborough, U.K., will be the location for a world-class science and technology park as development of a former AstraZeneca R&D site gets underway. Jayplas acquired the site in 2012 and has confirmed its plans to develop the site into a science park to be known as The Charnwood Biomedical Campus.

More... »

Transcelerate Biopharma recognizes CCRC, CPI certification for good clinical practice

Wednesday, January 15, 2014 11:19 AM

The Association of Clinical Research Professionals (ACRP) has learned that TransCelerate Biopharma now recognizes certification through the Certified Clinical Research Coordinator (CCRC) and Certified Physician Investigator (CPI) programs of ACRP's affiliate, the Academy of Clinical Research Professionals, as evidence of Good Clinical Practice (GCP) training.

More... »

Horizon Discovery, AstraZeneca ink agreement

Wednesday, January 8, 2014 01:26 PM

Horizon Discovery, a provider of research tools to support translational genomics research and the development of personalized medicines, and AstraZeneca have entered into a research, collaboration and license agreement to explore oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.

More... »

MedImmune, Immunocore enter immunotherapy agreement

Wednesday, January 8, 2014 01:21 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has entered into an oncology research collaboration and licensing agreement with Immunocore, a privately-held, U.K.-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.

More... »

Cancer Research U.K., AstraZeneca sign deal

Friday, January 3, 2014 02:46 PM

Cancer Research U.K. and Cancer Research Technology, the charity's development and commercialization arm, have reached an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.

More... »

Molecular Profiles joins consortium to drive pediatric formulation development

Thursday, January 2, 2014 10:30 AM

A collaborative pharmaceutical project focused on improving the pathway for developing pediatric formulations has been given the go-ahead after successfully securing an innovation grant.

More... »

AstraZeneca to acquire Bristol-Myers Squibb share of diabetes alliance assets

Friday, December 20, 2013 11:00 AM

AstraZeneca will acquire the entirety of Bristol-Myers Squibb's interest in the companies' diabetes alliance for $2.7 billion, and up to $1.4 billion in regulatory, launch and sales-related payments. AstraZeneca also has agreed to pay various sales-related royalty payments up until 2025 and may make payments up to $225 million when certain assets are subsequently transferred.

More... »

AstraZeneca donates Brixham Environmental Laboratory to Plymouth University

Monday, December 9, 2013 12:25 PM

AstraZeneca will donate its Environmental Laboratory in Brixham to Plymouth University to ensure the lab continues to serve scientific and research purposes.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs